ArticlePloS one2008
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis.PloS one · 2011Pooled it
- Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review.International journal of molecular sciences · 2021Review
- N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples.Translational cancer research · 2019Article
- Clusterin Silencing in Prostate Cancer Induces Matrix Metalloproteinases by an NF-Journal of oncology · 2019Article
- In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.International journal of molecular sciences · 2018Article
- Gene Expression Detection Assay for Cancer Clinical Use.Journal of Cancer · 2018Review
- Gas1 expression in parietal cells of Bowman's capsule in experimental diabetic nephropathy.Histochemistry and cell biology · 2017Article
- The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.BMC cancer · 2015Article
- Article
- Article
- Considerations for accurate gene expression measurement by reverse transcription quantitative PCR when analysing clinical samples.Analytical and bioanalytical chemistry · 2014Review
- Validation of novel reference genes for reverse transcription quantitative real-time PCR in drought-stressed sugarcane.TheScientificWorldJournal · 2014Article
- Growth arrest specific 1 (GAS1) is abundantly expressed in the adult mouse central nervous system.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Article
- Personalized medicine in screening for malignant disease: a review of methods and applications.Biomarker insights · 2013Article
- Regulation of miR106b cluster through the RB pathway: mechanism and functional targets.Cell cycle (Georgetown, Tex.) · 2013Article
- Identification of markers of prostate cancer progression using candidate gene expression.British journal of cancer · 2012Article
- Markers of field cancerization: proposed clinical applications in prostate biopsies.Prostate cancer · 2012Article
- Article
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.Oncogene · 2010Article
- Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay.Prostate cancer and prostatic diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP. METHODOLOGY/PRINCIPAL
findingsThe 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained with 10-fold cross-validation procedure. CaP versus benign specimens were discriminated with (80+/-5)% accuracy, (81+/-6)% sensitivity and (78+/-7)% specificity. The method also correctly classified 71% of patients with Gleason score<7 versus > or =7, an important predictor of final outcome. CONCLUSIONS/SIGNIFICANCE: The method showed high sensitivity in a collection of specimens in which a significant portion of the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports the notion of the "cancer field effect", in which transformed cells extend beyond morphologically evident tumour. The molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations are needed, this method poses the potential to enhance conventional diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.